A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin®) in cancer patients
Masashi Kanai(Kyoto University Hospital), Hiroyuki Shibata(Akita University)
Cited by 191
Related Papers
Curcumin β‐D‐glucuronide exhibits anti–tumor effects on oxaliplatin‐resistant colon cancer with less toxicity in vivo
|Cancer Science|2020|29
Pyrolyzed deketene curcumin controls regulatory T cell generation and gastric cancer metabolism cooperate with 2-deoxy-d-glucose
|Frontiers in Immunology|2023|16